Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
Authors:
- Massimiliano GrecoMGMassimiliano Greco
- Silvia De RosaSRSilvia De Rosa
- Fabian BoehmFBFabian Boehm
- Sofia SpanoSSSofia Spano
- Romina AcetoRARomina Aceto
- Antonio VozaAntonio Voza
- Francesco ReggianiFRFrancesco Reggiani
- Marta CalatroniMCMarta Calatroni
- Gianluca CastellaniGCGianluca Castellani
- Elena CostantiniECElena Costantini
- Gianluca VillaGVGianluca Villa
- Maurizio CecconiMCMaurizio Cecconi
Open Access
- 15 January 2023
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 317
Abstract
Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population.Keywords
This publication has 33 references indexed in Scilit:
- The definition of acute kidney injury and its use in practiceKidney International, 2015
- Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkersNephrology Dialysis Transplantation, 2014
- World Incidence of AKIClinical Journal of the American Society of Nephrology, 2013
- Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Critical Care, 2013
- KDIGO Clinical Practice Guidelines for Acute Kidney InjuryNephron Clinical Practice, 2012
- Adding insult to injury: care of patients with acute kidney injuryBritish Journal of Hospital Medicine, 2009
- Reduced Production of Creatinine Limits Its Use as Marker of Kidney Injury in SepsisJournal of the American Society of Nephrology, 2009
- Mechanical Ventilation and Lung–Kidney InteractionsClinical Journal of the American Society of Nephrology, 2008
- Treatment of acute renal failureKidney International, 1998
- The Elderly PatientDrugs, 1986